NCS Multistage posts Q4 net income of USD 15.0 million (+328%)

Reuters
03/05
NCS Multistage posts Q4 net income of USD 15.0 million (+328%)

NCS Multistage reported Q4 2025 total revenues of USD 50.6 million (+13%), with operating income of USD 5.2 million (+78%) and net income of USD 15.0 million, including a USD 9.8 million net positive impact from releasing its deferred tax valuation allowance. Q4 adjusted EBITDA was USD 9.2 million, and the company ended 2025 with USD 36.7 million in cash and USD 7.6 million in debt. For FY 2025, NCS Multistage posted total revenues of USD 183.6 million (+13%), operating income of USD 10.5 million (more than doubled), and net income of USD 23.7 million, including a USD 11.5 million net positive impact from the deferred tax valuation allowance release. FY adjusted EBITDA was USD 26.7 million (+20%) and free cash flow after distributions to non-controlling interest was USD 18.9 million. Business highlights included the July 31, 2025 acquisition of Reservoir Metrics (ResMetrics), which contributed USD 5.2 million to 2025 services revenue and USD 2.8 million in Q4 services revenue, strengthening NCS Multistage’s tracer diagnostics offering and expanding its presence in Middle East markets. Management said it expects a challenging 2026 market environment, with lower year-over-year U.S. customer activity, relatively flat Canada activity, and international improvements weighted to the second half, particularly in the Middle East.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NCS Multistage Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041605PRIMZONECNPR____9665959) on March 04, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10